ALS: Insights and innovations in treatment and research

ALS remains one of the most challenging neurodegenerative diseases, with limited treatment options and a progressive course that affects motor function, breathing, and quality of life. However, the research landscape is shifting. Genetically targeted therapies, such as tofersen for SOD1-associated ALS, are demonstrating that identifying the genetic basis of a patient's disease can open the door to more precise interventions.

In this report, we explore the full spectrum of ALS, from disease biology and genetic underpinnings to the current treatment landscape and the clinical trials shaping the next generation of care.

Key Takeaways

• Genetic Focus: Modern ALS research is increasingly focused on identifying specific gene mutations to develop targeted therapies.
• New Treatments: Recent FDA approvals, including Qalsody and Relyvrio, represent significant milestones in ALS clinical care.
• Clinical Innovation: A robust pipeline of experimental therapies and ongoing clinical trials offers new hope for disease management.
• Proactive Support: Programs like "Light the Way" provide essential resources and genetic testing for individuals at risk of familial ALS.

The report addresses the following areas, each relevant to research planning, patient support, or treatment evaluation:

• Overview of ALS demographics, disease burden, and societal impact
• Insights into the genetic causes of familial ALS, including the role of SOD1, C9orf72, and other gene mutations linked to disease onset
• Review of current FDA-approved treatments, including Qalsody (tofersen), Radicava (edaravone), Riluzole, and Nuedexta (with external link to ALS Association medication page)
• The role of genetic testing in identifying patients eligible for targeted therapies
• Future prospects with ongoing clinical trials and experimental therapies
• Information on Sano's commitment to supporting individuals at risk of genetic ALS through Light the Way

Why genetics are reshaping ALS research

While ALS has historically been treated as a single disease, advances in genetics are revealing distinct subtypes that respond to different therapeutic approaches. The FDA's 2023 approval of Qalsody (tofersen) for SOD1-associated ALS marked a turning point: the first genetically targeted therapy for a specific form of the disease.

Long-term follow-up data, published in late 2025, showed that sustained tofersen treatment delayed symptom progression and, in a subset of participants, led to stabilization or improvement over several years. These results are unprecedented for ALS and underscore a broader principle: when the genetic basis of a patient's disease is identified, more targeted and effective interventions become possible.

This shift has significant implications for clinical research. Trials targeting genetic subtypes of ALS require patients to undergo genetic testing before eligibility can be confirmed. Identifying and engaging these patients, particularly those who may carry relevant mutations but have not yet been tested, is one of the central operational challenges in precision ALS research.

Our report explores these dynamics in detail, alongside the broader treatment landscape and the evolving role of genetic testing in ALS care.

Sano Genetics works with sponsors and research organizations to support the identification and engagement of patients with genetic forms of ALS. Through programs like Light the Way, Sano helps connect individuals at risk of genetic ALS with testing, counseling, and research opportunities. To learn more about how Sano supports precision medicine programs in neurodegenerative disease, get in touch.

Download the full report for a detailed overview of the ALS landscape, current treatments, genetic research, and the clinical programs shaping future care.